Bevacizumab (Avastin, Genentech) has been approved by the FDA in combination with a 5-fluorouracil (5-FU)-based chemotherapy regimen as a second-line treatment for metastatic colorectal cancer. The phase III trial that led to the approval of the therapy evaluated 829 patients who received either bevacizumab plus FOLFOX4 (oxaliplatin, 5-FU, leucovorin) or FOLFOX4 alone and who were previously treated with irinotecan (Camptosar, Pfizer) and 5-FU as their initial therapy for metastatic disease or as adjuvant therapy. Results showed a 33% improvement in survival for the combination regimen. Median survival was 13 months versus 10.8 months.
Avastin plus 5-FU regimen OK'd as second-line therapy
Bevacizumab (Avastin, Genentech) has been approved by the FDA in combination with a 5-fluorouracil (5-FU)-based chemotherapy regimen as a second-line treatment for metastatic colorectal cancer. The phase III trial that led to the approval of the therapy evaluated 829 patients who received either bevacizumab plus FOLFOX4 (oxaliplatin, 5-FU, leucovorin) or FOLFOX4 alone and who were previously treated with irinotecan (Camptosar, Pfizer) and 5-FU as their initial therapy for metastatic disease or as adjuvant therapy. Results showed a 33% improvement in survival for the combination regimen. Median survival was 13 months versus 10.8 months. Bevacizumab is a vascular endothelial growth factor inhibitor that is also approved as a first-line treatment of metastatic colorectal cancer in combination with 5-FU-based chemotherapy.
To see more Hot off the Press news articles, click here http://www.drugtopics.com/Hot+off+the+Press.
Q&A: Retail, Independent Pharmacies Continue to Call for Improved Reimbursement Practices
June 30th 2025Rick Gates, chief pharmacy officer at Walgreens and chairman of the National Association of Chain Drug Stores, discussed the current status of retail pharmacies and the way they are reimbursed.